AVITA Medical, Inc. (RCEL) Tops Q4 EPS by 10c ; Offers Guidance

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q4 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.1 million versus the consensus estimate of $14.43 million.

GUIDANCE:

AVITA Medical, Inc. sees Q1 2024 revenue of $14.8-15.6 million, versus the consensus of $14.3 million.

AVITA Medical, Inc. sees FY2024 revenue of $78.5-84.5 million, versus the consensus of $71.98 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’